Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

STRONGBRIDGE BIOPHARMA PLC

(SBBP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Form 8.3 - The Vanguard Group, Inc. : Strongbridge Biopharma plc

06/11/2021 | 08:58am EDT
The Vanguard Group, Inc. ( IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc 
11-Jun-2021 / 13:56 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ap19 
 
FORM 8.3 
 
IRISH TAKEOVER PANEL 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
 
1.  KEY INFORMATION 
 
Name of person dealing (Note 1)                                                  The Vanguard Group, Inc. 
Company dealt in                                                                 Strongbridge Biopharma plc 
Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.01 Ordinary Shares 
Date of dealing                                                                  09 June 2021 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                             Long            Short 
                                             Numbers   (%)   Numbers (%) 
(1) Relevant securities                      2,315,587 3.42% 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total                                        2,315,587 3.42% 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:                  Long        Short 
                                             Numbers (%) Numbers (%) 
(1) Relevant securities 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total 

Ap20

1. Dealings (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities  Price per unit (Note 5) 
Sale          490                            2.86 USD 
Purchase      16                             2.86 USD 

(b) Derivatives transactions (other than options transactions)

Product name,  Nature of transaction Number of relevant securities Price per unit 
e.g. CFD       (Note 6)              (Note 7)                      (Note 5) 
Not Applicable 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, Writing, selling,    Number of securities to               Type, e.g.               Option money paid/ 
              purchasing, varying  which the option relates     Exercise American,         Expiry received per unit 
e.g. call     etc.                 (Note 7)                     price    European etc.     date   (Note 5) 
option 
Not 
Applicable 

(ii) Exercising

Product name,                         Exercise price per unit (Note 5) 
                 Number of securities 
e.g. call option 
Not Applicable 

(e) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction         Price per unit 
                      Details 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
 
 
 

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure                                               11 June 2021 
Contact name                                                     Shawn Acker 
Telephone number                                                 001-610-669-8989 
If a connected EFM, name of offeree/offeror with which connected 
If a connected EFM, state nature of connection (Note 10) ----------------------------------------------------------------------------------------------------------------------- 
Category Code: RET - Strongbridge Biopharma plc 
TIDM:          IRSH 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  110886 
EQS News ID:   1207187 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1207187&application_name=news 
 

(END) Dow Jones Newswires

June 11, 2021 08:57 ET (12:57 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
STRONGBRIDGE BIOPHARMA PLC 2.11% 2.9 Delayed Quote.19.34%
All news about STRONGBRIDGE BIOPHARMA PLC
06/18FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
06/16FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
06/14FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
06/11FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
06/08FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
06/04STRONGBRIDGE BIOPHARMA  : Announces Issuance of Patent for RECORLEV (levoketocon..
AQ
06/03STRONGBRIDGE BIOPHARMA  : Receives US Patent for Treating Cushing's Syndrome wit..
MT
06/03Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoke..
GL
06/03FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
05/31FORM 8.3 - THE VANGUARD GROUP, INC.  : Strongbridge Biopharma plc
DJ
More news
Financials (USD)
Sales 2021 36,3 M - -
Net income 2021 -36,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,51x
Yield 2021 -
Capitalization 197 M 197 M -
Capi. / Sales 2021 5,42x
Capi. / Sales 2022 3,23x
Nbr of Employees 72
Free-Float 88,5%
Chart STRONGBRIDGE BIOPHARMA PLC
Duration : Period :
Strongbridge Biopharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STRONGBRIDGE BIOPHARMA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,60 $
Last Close Price 2,90 $
Spread / Highest target 245%
Spread / Average Target 93,1%
Spread / Lowest Target 12,1%
EPS Revisions
Managers and Directors
NameTitle
John H. Johnson Chief Executive Officer & Director
Richard S. Kollender President & Chief Financial Officer
Garheng Kong Chairman
Fredric Cohen Chief Medical Officer
Brian Conner Chief Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
STRONGBRIDGE BIOPHARMA PLC19.34%197
CSL LIMITED7.89%104 078
WUXI BIOLOGICS (CAYMAN) INC.28.50%71 827
BIOGEN INC.58.64%58 481
SAMSUNG BIOLOGICS CO.,LTD.1.21%48 692
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.49%44 555